Navigation Links
Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
Date:3/11/2013

Aliso Viego, CA (PRWEB) March 11, 2013

Histogen Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, has partnered with a Southern California medical device executive management and investment group to establish PUR Biologics, LLC. PUR is a joint venture focused on the emerging field of biologics for musculoskeletal conditions, including spine, dental and medical device applications.

Under this joint venture, PUR Biologics has acquired exclusive worldwide rights to Histogen’s human multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials for use in the orthopedic areas of bone, cartilage, spinal disc and ligament regeneration, as well as device coatings. A soluble composition of naturally-secreted proteins, the CCM contains growth factors such as follistatin and stem cell factor which are known to stimulate stem cell growth, differentiation, and tissue regeneration. The insoluble ECM, made up of a variety of collagens and other matrix proteins, holds promise as an excellent biologically-active filler, attracting fibroblasts and stem cells as well as supporting new tissue growth.

“Regenerative technologies are paramount in advancing the current state or orthopedics and neurosurgery,” said Dr. Chad Prusmack Chief of Neurosurgery at Rocky Mountain Spine Clinic and consultant to the Denver Broncos. “The use of naturally-secreted human growth factors and matrix proteins, known to stimulate and support stem cell growth in the body, can prove to be transformational in the regeneration of multiple musculoskeletal and neuronal tissues .These unique preparations may be the universal 'transducer' needed for optimizing directed stem cell differentiation and healthy proliferation."

PUR Biologics will build upon early proof-of-concept data to bring orthopedic products based on the CCM and ECM through all stages of development and commercialization. The Company’s first research and development efforts will be in the area of bone regeneration, which has potential benefit in a number of orthopedic applications.

The joint venture will be managed and funded by Histogen’s partner group, made up of experts from the surgery and medical device industries. Ryan Fernan, CEO of the newly-created PUR Biologics, has spent more than a decade in medical sales and management, including bringing OC Surgical from a fledgling medical device distributorship to a multi-million dollar orthopedic business during his time as President of the Company. PUR Biologics’ management and investment group has a proven track record synergistically packaging technologies and advancements in surgery to serve unmet medical needs.

"We are extremely excited to have access to Histogen's groundbreaking scientific platform,” said Ryan Fernan. “Coupled with our extensive experience in product development, sales, and distribution, this will be a powerful relationship that will fuel development of much needed innovation in this space."

The creation of PUR Biologics allows Histogen to support the research required to bring its biologic products toward commercialization in the rapidly growing multi-billion dollar orthopedic market, while continuing to dedicate resources to the Company’s other promising aesthetic and therapeutic programs.

“Histogen’s preliminary studies have shown that our human CCM and ECM materials support stem cell growth and differentiation into bone and other structural tissues, making orthopedics a promising and exciting area of research for our products,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “This joint venture provides Histogen the opportunity to see its innovative cell-derived products make strides in the large and important orthopedic market, while continuing to focus on development of its hair growth, skincare and oncology applications.”

About PUR Biologics
PUR Biologics is dedicated to providing regenerative biologic solutions to address musculoskeletal surgical needs, including spine, dental, ligament and medical device coating applications. In addition to distribution of approved allograft and biologic products, PUR is focused on development of next-generation orthopedic products based upon human protein and growth factor materials for bone and tissue regeneration. For more information visit http://www.purbiologics.com.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10514524.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Harvards Wyss Institute creates living human gut-on-a-chip
2. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
3. Plasma startup creates high-energy light to make smaller microchips
4. UMD creates new tech for complex micro structures for use in sensors & other apps
5. Harvards Wyss Institute team creates versatile 3d nanostructures using DNA bricks
6. Fitting smart mobile phone with magnifying optics creates real cell phone
7. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
9. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. Adeona Becomes Synthetic Biologics, Inc.
11. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/18/2017)... IL (PRWEB) , ... February 17, 2017 , ... ... Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow ... Convention Center in Orlando, Fla. , The combined scientific sessions offer ...
(Date:2/18/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... FREMONT, Calif. , Feb. 17, 2017 /PRNewswire/ ... pleased to announce development of a novel system ... in collaboration with the University of Rochester (NY, ... ). The new system is able to ... cancer biomarker, HER2 (Human epidermal growth factor receptor-2) ...
Breaking Biology Technology:
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
Breaking Biology News(10 mins):